Neurotechnology startup Synchron is making a huge move for increased production of its groundbreaking brain-computer interface (BCI), the Synchron Switch, as it advances towards the commercialization phase.
A recent announcement revealed Synchron's recent acquisition of a minority equity stake in the German manufacturing company Acquandas, renowned for its unique ability to layer metals crucial for the company's implant component.
Access to Exclusive Layering Technology
In a significant development, Synchron secures a minority equity stake in Acquandas, providing exclusive access to the manufacturer's advanced layering technology for medical devices, per CNBC.
Synchron's CEO, Tom Oxley, and CTO, Riki Banerjee, will join Acquandas' board. This is expected to bolster their implantable neurotechnology over their competitors.
Innovation with Synchron Switch
Neuralink CEO Elon Musk previously approached Synchron for a possible collaboration in 2022. However, nothing much happened about this deal in the new reports.
When it comes to technology, Synchron offers its flagship BCI, the Synchron Switch which resembles a stent-like device inserted through a patient's blood vessels. This innovative product empowers individuals with limited physical mobility, enabling them to control smart home devices and cursors through mind-operated commands.
Initial studies involved successful implantations in the U.S. and Australia, laying the foundation for broader regulatory approval.
Speaking of which, Synchron was able to implant a brain-computer interface in the first 6 patients in the US last year. This gave hope to paralyzed people to perform daily tasks with ease.
Patient Registry Launch
As Synchron intensifies manufacturing efforts, it simultaneously aims to connect with potential patients. The launch of an official patient registry in mid-February serves as a mechanism for individuals with limb or motor impairment to express interest, stay informed about trials, and contribute valuable insights. This patient-centric approach aids in shaping considerations for prioritized clinical sites across the U.S.
Attracting Investments and Industry Attention
Synchron has garnered attention from influential investors, signaling confidence in its groundbreaking technology. A $75 million financing round in 2022 included investments from Bill Gates' and Jeff Bezos' investment firms.
Differentiated Approach in BCI Implantation
Synchron's BCI distinguishes itself with a less-invasive approach compared to counterparts like Neuralink. The Stentrode, a stent utilized by Synchron, is equipped with tiny sensors and is inserted near the motor cortex through existing endovascular techniques.
While the brain signals may not be as strong as direct brain tissue implants, the minimally invasive procedure enhances accessibility.
Balancing Signal Quality and Accessibility
Synchron acknowledges the trade-off between signal strength and accessibility. While the signals may not match the intensity of direct brain tissue implants, the team believes that the less-invasive procedure offers a strategic advantage by making the technology more accessible to a broader demographic.
Outside the US, even Chinese researchers have plans to overtake Musk's Neuralink. The country's China's Ministry of Industry and Information Technology intends to launch the brain-interface products by 2025.
